Castle Biosciences Balance Sheet Health

Financial Health criteria checks 5/6

Castle Biosciences tiene unos fondos propios totales de $385.8M y una deuda total de $0.0, lo que sitúa su ratio deuda/fondos propios en 0%. Sus activos y pasivos totales son $436.0M y $50.2M respectivamente.

Key information

Debt to equity ratio

US$0

Debt

Interest coverage ratio	n/a
Cash	US$243.10m
Equity	US$391.27m
Total liabilities	US$62.07m
Total assets	US$453.34m

Recent financial health updates

Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans

Oct 31

Recent updates

Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects

Jan 27

Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans

Oct 31

Earnings Working Against Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Following 36% Dive

Jun 13

Analysts Just Published A Bright New Outlook For Castle Biosciences, Inc.'s (NASDAQ:CSTL)

Aug 14

Financial Position Analysis

Pasivos a corto plazo: CSTLLos activos a corto plazo ($279.6M) de la empresa superan a sus pasivos a corto plazo ($36.3M).

Pasivo a largo plazo: CSTLLos activos a corto plazo ($279.6M) superan a sus pasivos a largo plazo ($13.9M).

Debt to Equity History and Analysis

Nivel de deuda: CSTL está libre de deudas.

Reducción de la deuda: CSTL actualmente no tiene deuda, sin embargo no podemos comparar con hace 5 años ya que no tenemos datos de ese periodo.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Cash runway estable: CSTL tiene suficiente cash runway para más de 3 años basándose en su free cash flow actual.

Pronóstico de cash runway: Datos insuficientes para determinar si CSTL tiene suficiente margen de liquidez en caso de que su flujo de caja libre siga creciendo o disminuyendo en función de las tasas históricas.

Discover healthy companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Castle Biosciences Balance Sheet Health

Financial Health criteria checks 5/6

Key information

Recent financial health updates

Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans

Recent updates

Independent Chairman of the Board notifies of intention to sell stock

Castle Biosciences, Inc. Announces Share New Data At the 20Th European Association of Dermato-Oncology Congress

Castle Biosciences, Inc. Announces Board Changes

Castle Biosciences, Inc. Announces the Publication of a New Multi-Center Performance Study of its DecisionDx-SCC Risk Stratification Test

Founder notifies of intention to sell stock

Consensus estimates of losses per share improve by 26%

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Castle Biosciences, Inc. Provides Revenue Guidance for the Full Year 2024

Castle Biosciences, Inc. to Report Second Half, 2023 Results on Feb 28, 2024

Independent Chairman of the Board notifies of intention to sell stock

Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects

Castle Biosciences, Inc. Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii

Castle Biosciences, Inc. Provides Revenue Guidance for the Year 2023

Forecast to breakeven in 2026

Founder exercised options and sold US$362k worth of stock

Independent Chairman of the Board notifies of intention to sell stock

Founder notifies of intention to sell stock

Castle Biosciences, Inc. Announces Data from A Single-Site, Open-Label Study Demonstrating the Consistent Impact of Idgenetix®? on Medication Response and Remission Rates in Patients with Major Depressive Disorder

Consensus estimates of losses per share improve by 21%

Castle Biosciences, Inc. Announces New Data Showing the Ability of Its Pipeline Test in Development to Distinguish Between Responders and Non-Responders to an Atopic Dermatitis

New minor risk - Shareholder dilution

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Castle Biosciences, Inc. Raises Earnings Guidance for the Full Year 2023

Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans

Castle Biosciences, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Castle Biosciences, Inc. Announces New Study Demonstrating DecisionDx-Melanoma Outperforms a Nomogram Developed at the Memorial Sloan Kettering Cancer Center

Castle Biosciences, Inc. Shares New Data Demonstrating Ability of TissueCypher Test Results to Inform Clinical Decision-Making in Patients with Non-Dysplastic Barrett's Esophagus

Castle Biosciences, Inc. Announces TissueCypher Barrett’s Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett’s Esophagus

Castle Biosciences, Inc. Announces Data from a Study Showing the Addition of Drug-Drug Interactions and Lifestyle Factors to Drug-Gene Interactions

Consensus estimates of losses per share improve by 12%

Founder notifies of intention to sell stock

Castle Biosciences, Inc. Raises Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Independent Chairman of the Board notifies of intention to sell stock

Castle Biosciences to Present New DecisionDx®-Melanoma Data at the American Head & Neck Society's 11th International Conference on Head and Neck Cancer

Earnings Working Against Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Following 36% Dive

Castle Biosciences, Inc. Presents New Data Demonstrating the Ability of DecisionDx-SCC to Identify Tumors Likely to Metastasize in Patients with Cutaneous Squamous Cell Carcinoma Deemed Low Risk by Traditional Staging

Independent Director recently bought US$69k worth of stock

Price target decreased by 11% to US$39.75

Castle Biosciences, Inc. to Share New Data on DecisionDx-Melanoma and DecisionDx-UM at the 2023 ASCO Annual Meeting

Consensus EPS estimates fall by 16%, revenue upgraded

Founder notifies of intention to sell stock

Castle Biosciences, Inc. Reaffirms Revenue Guidance for the Full Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 11%, revenue upgraded

Full year 2022 earnings: EPS exceeds analyst expectations

Castle Biosciences, Inc. Publishes Data from Prospective, Multicenter Study, Called DECIDE

Castle Biosciences, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Founder notifies of intention to sell stock

Castle Biosciences, Inc. Revises Revenue Guidance for the for Full-Year 2022

Founder exercised options and sold US$141k worth of stock

Castle Biosciences Presents New Data Demonstrating the Clinical Utility and Value of DecisionDx®-SCC in Moderately and Poorly Differentiated Cutaneous Squamous Cell Carcinoma Tumors

Founder notifies of intention to sell stock

Founder notifies of intention to sell stock

Independent Chairman of the Board notifies of intention to sell stock

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Castle Biosciences, Inc. Revises Revenue Guidance for the Full Year 2022

Castle Biosciences, Inc. Presents New Data from Collaboration with the National Cancer Institute's (NCI) Surveillance, Epidemiology and End Results (SEER) Program

Castle Biosciences, Inc. Announces New Data Showing That the Use of Tissuecypher® Barrett’S Esophagus Test Results Can Significantly Improve Management Decisions for Barrett’S Esophagus (Be) Patients with Low-Grade Dysplasia (Lgd)To Improve Health Outcomes

Castle Biosciences, Inc. Announces New Data from Prospective, Multicenter DECIDE1 Study

Castle Biosciences, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Castle Biosciences, Inc. Announces Results from a Randomized Controlled Trial Show That TissueCypher® Barrett’s Esophagus Test Results Can Significantly Improve the Accuracy of Risk Assessments and Adherence to Guideline-Recommended Patient Management

Castle Biosciences, Inc. to Present Data Supporting the Clinical Value of Its Suite of Skin Cancer Tests through Multiple Oral Presentations at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting

Castle Biosciences Announces Publication of Study Demonstrating the Integration of DecisionDx(R)-Melanoma and Clinicopathologic Factors Provides Optimized, Survival Prognoses for Patients with Cutaneous Melanoma

Castle Biosciences, Inc. Presents Clinical Use Scenarios for Its Diagnostic Gene Expression Profile Tests At Maui Derm Np+Pa Fall 2022 Conference

Consensus revenue estimates increase by 10%

Analysts Just Published A Bright New Outlook For Castle Biosciences, Inc.'s (NASDAQ:CSTL)

Castle Biosciences, Inc. Revises Earnings Guidance for the Full Year 2022

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Castle Biosciences Q2 2022 Earnings Preview

Founder notifies of intention to sell stock

Is There Now An Opportunity In Castle Biosciences, Inc. (NASDAQ:CSTL)?

Castle Biosciences, Inc. to Report Q2, 2022 Results on Aug 08, 2022